Separately, Zacks Investment Research upgraded shares of Mesoblast from a “sell” rating to a “hold” rating in a research note on Tuesday, February 15th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $9.83.
NASDAQ MESO opened at $3.87 on Friday. The firm has a 50-day moving average of $4.21 and a 200-day moving average of $4.93. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.88 and a current ratio of 1.88. The stock has a market cap of $503.45 million, a PE ratio of -5.09 and a beta of 3.17. Mesoblast has a 52-week low of $3.55 and a 52-week high of $8.99.
A number of hedge funds have recently added to or reduced their stakes in MESO. Morgan Stanley increased its holdings in Mesoblast by 16.6% in the 1st quarter. Morgan Stanley now owns 51,715 shares of the company’s stock valued at $428,000 after buying an additional 7,369 shares during the period. Cambridge Investment Research Advisors Inc. bought a new position in Mesoblast in the 3rd quarter valued at about $66,000. M&G Investment Management Ltd. increased its holdings in Mesoblast by 66.5% in the 3rd quarter. M&G Investment Management Ltd. now owns 1,320,000 shares of the company’s stock valued at $7,920,000 after buying an additional 527,005 shares during the period. BlackRock Inc. increased its holdings in Mesoblast by 3.3% in the 3rd quarter. BlackRock Inc. now owns 807,470 shares of the company’s stock valued at $4,853,000 after buying an additional 26,032 shares during the period. Finally, Hennion & Walsh Asset Management Inc. increased its holdings in Mesoblast by 12.7% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 390,407 shares of the company’s stock valued at $2,346,000 after buying an additional 43,933 shares during the period. 2.72% of the stock is currently owned by hedge funds and other institutional investors.
About Mesoblast (Get Rating)
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases.
- Get a free copy of the StockNews.com research report on Mesoblast (MESO)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.